BUKWANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,130 KRW | -0.49% |
|
+3.03% | +0.49% |
| Sales 2022 | 191B 139M | Sales 2023 | 126B 91.93M | Capitalization | 418B 305M |
|---|---|---|---|---|---|
| Net income 2022 | -2.48B -1.81M | Net income 2023 | -31.33B -22.87M | EV / Sales 2022 | 2.69 x |
| Net cash position 2022 | 84.59B 61.75M | Net cash position 2023 | 71.84B 52.44M | EV / Sales 2023 | 2.75 x |
| P/E ratio 2022 |
-242
x | P/E ratio 2023 |
-13.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.5% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.49% | ||
| 1 week | +3.03% | ||
| Current month | -7.96% | ||
| 1 month | -8.51% | ||
| 3 months | -10.90% | ||
| 6 months | +10.05% | ||
| Current year | +0.49% |
1 week
5 960.00
6 230.00
1 month
5 810.008 240.00
Current year
5 810.009 000.00
1 year
5 460.009 000.00
3 years
5 460.0023 500.00
5 years
5 460.0042 318.18
10 years
5 460.0042 318.18
| Managers | Title | Age | Since |
|---|---|---|---|
Hee-Won Yoo
CEO | Chief Executive Officer | 59 | - |
Woo-Hyun Lee
CEO | Chief Executive Officer | 56 | - |
Sang-Hoon Kim
PSD | President | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Soo Chung
PRN | Corporate Officer/Principal | 87 | - |
Dong-Yeon Kim
PRN | Corporate Officer/Principal | 86 | - |
Sang-Hoon Kim
PSD | President | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 6,130 | -0.49% | 136,454 |
| 24-04-22 | 6,160 | +2.84% | 147,933 |
| 24-04-19 | 5,990 | -1.64% | 118,412 |
| 24-04-18 | 6,090 | +1.50% | 149,263 |
| 24-04-17 | 6,000 | +0.84% | 838,797 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
Bukwang Pharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +0.49% | 306M | |
| +18.46% | 42.77B | |
| +20.21% | 22.23B | |
| +12.34% | 14.44B | |
| +11.07% | 13.05B | |
| +36.35% | 11.59B | |
| -8.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +5.03% | 4.97B |
- Stock Market
- Equities
- A003000 Stock
